Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children

Angela L. Ngai, Brenda O. Staehle, Barbara J. Kuter, Nancy M. Cyanovich, Iksung Cho, Holly Matthews, Paul Keller, Ann M. Arvin, Barbara Watson, C. J. White, Renner Anderson, Allan Arbeter, Steven Black, Stan L. Block, Dean A Blumberg, Philip A. Brunell, Steven A. Chartrand, Dennis A. Clements, Penelope Dennehy, Harry KeyserlingBeth Nauert, Keith S. Reisinger, Margaret B. Rennels, Peter D. Reuman, Ziad M. Shehab, Stuart E. Starr, Richard Tucker

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. To compare the safety and immunogenicity of a one- vs. two- dose regimen of Oka/Merck varicella vaccine in approximately 2000 healthy children 12 months to 12 years of age. Methodology. Subjects with a negative history of varicella were randomized to receive either one or two injections of the vaccine given 3 months apart and were followed for clinical reactions and serologic response (glycoprotein-based enzyme-linked immunosorbent assay). Results. Both one- and two-dose vaccine regimens were generally well- tolerated. The incidences of varicelliform rash and fever were less frequent after the second injection. However, as light increase in the incidence of injection site reactions was noted after the second injection; these were generally mild. Seroconversion rates by glycoprotein-based enzyme-linked immunosorbent assay were 98.2% (1700 of 1731) after one injection and 99.9% (717 of 718) after two injections. A significant (P < 0.001) boost in geometric mean titers was observed in children who received a second injection of vaccine 3 months after the first injection. Of the children who seroconverted at 6 weeks postregimen (one or two doses as assigned), 99.8% (528 of 529) of the one-dose group and 99.8% (473 of 474) of the two-dose group maintained antibody to varicella at 1 year with geometric mean titers of 19.5 and 31.2, respectively. Conclusions. Administration of a one- or two- dose regimen of the live Oka/Merck varicella vaccine (VARIVAX®) is immunogenic and is generally well-tolerated in healthy children 1 to 12 years old. Antibody to varicella persists in >99% of vaccinees 1 year after vaccination regardless of a one- or two-dose regimen. Long-term follow-up studies of this cohort of children may determine whether a two-dose regimen offers superior protection against chickenpox.

Original languageEnglish (US)
Pages (from-to)49-54
Number of pages6
JournalPediatric Infectious Disease Journal
Volume15
Issue number1
DOIs
StatePublished - 1996

Fingerprint

Chickenpox Vaccine
Safety
Injections
Chickenpox
Glycoproteins
Vaccines
Enzyme-Linked Immunosorbent Assay
Incidence
Exanthema
Vaccination
Fever
Light

Keywords

  • children
  • immunization
  • vaccine
  • Varicella
  • varicella vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Ngai, A. L., Staehle, B. O., Kuter, B. J., Cyanovich, N. M., Cho, I., Matthews, H., ... Tucker, R. (1996). Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatric Infectious Disease Journal, 15(1), 49-54. https://doi.org/10.1097/00006454-199601000-00011

Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. / Ngai, Angela L.; Staehle, Brenda O.; Kuter, Barbara J.; Cyanovich, Nancy M.; Cho, Iksung; Matthews, Holly; Keller, Paul; Arvin, Ann M.; Watson, Barbara; White, C. J.; Anderson, Renner; Arbeter, Allan; Black, Steven; Block, Stan L.; Blumberg, Dean A; Brunell, Philip A.; Chartrand, Steven A.; Clements, Dennis A.; Dennehy, Penelope; Keyserling, Harry; Nauert, Beth; Reisinger, Keith S.; Rennels, Margaret B.; Reuman, Peter D.; Shehab, Ziad M.; Starr, Stuart E.; Tucker, Richard.

In: Pediatric Infectious Disease Journal, Vol. 15, No. 1, 1996, p. 49-54.

Research output: Contribution to journalArticle

Ngai, AL, Staehle, BO, Kuter, BJ, Cyanovich, NM, Cho, I, Matthews, H, Keller, P, Arvin, AM, Watson, B, White, CJ, Anderson, R, Arbeter, A, Black, S, Block, SL, Blumberg, DA, Brunell, PA, Chartrand, SA, Clements, DA, Dennehy, P, Keyserling, H, Nauert, B, Reisinger, KS, Rennels, MB, Reuman, PD, Shehab, ZM, Starr, SE & Tucker, R 1996, 'Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children', Pediatric Infectious Disease Journal, vol. 15, no. 1, pp. 49-54. https://doi.org/10.1097/00006454-199601000-00011
Ngai, Angela L. ; Staehle, Brenda O. ; Kuter, Barbara J. ; Cyanovich, Nancy M. ; Cho, Iksung ; Matthews, Holly ; Keller, Paul ; Arvin, Ann M. ; Watson, Barbara ; White, C. J. ; Anderson, Renner ; Arbeter, Allan ; Black, Steven ; Block, Stan L. ; Blumberg, Dean A ; Brunell, Philip A. ; Chartrand, Steven A. ; Clements, Dennis A. ; Dennehy, Penelope ; Keyserling, Harry ; Nauert, Beth ; Reisinger, Keith S. ; Rennels, Margaret B. ; Reuman, Peter D. ; Shehab, Ziad M. ; Starr, Stuart E. ; Tucker, Richard. / Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. In: Pediatric Infectious Disease Journal. 1996 ; Vol. 15, No. 1. pp. 49-54.
@article{b2013b80b14b438d980ebc04d806e1d3,
title = "Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children",
abstract = "Objective. To compare the safety and immunogenicity of a one- vs. two- dose regimen of Oka/Merck varicella vaccine in approximately 2000 healthy children 12 months to 12 years of age. Methodology. Subjects with a negative history of varicella were randomized to receive either one or two injections of the vaccine given 3 months apart and were followed for clinical reactions and serologic response (glycoprotein-based enzyme-linked immunosorbent assay). Results. Both one- and two-dose vaccine regimens were generally well- tolerated. The incidences of varicelliform rash and fever were less frequent after the second injection. However, as light increase in the incidence of injection site reactions was noted after the second injection; these were generally mild. Seroconversion rates by glycoprotein-based enzyme-linked immunosorbent assay were 98.2{\%} (1700 of 1731) after one injection and 99.9{\%} (717 of 718) after two injections. A significant (P < 0.001) boost in geometric mean titers was observed in children who received a second injection of vaccine 3 months after the first injection. Of the children who seroconverted at 6 weeks postregimen (one or two doses as assigned), 99.8{\%} (528 of 529) of the one-dose group and 99.8{\%} (473 of 474) of the two-dose group maintained antibody to varicella at 1 year with geometric mean titers of 19.5 and 31.2, respectively. Conclusions. Administration of a one- or two- dose regimen of the live Oka/Merck varicella vaccine (VARIVAX{\circledR}) is immunogenic and is generally well-tolerated in healthy children 1 to 12 years old. Antibody to varicella persists in >99{\%} of vaccinees 1 year after vaccination regardless of a one- or two-dose regimen. Long-term follow-up studies of this cohort of children may determine whether a two-dose regimen offers superior protection against chickenpox.",
keywords = "children, immunization, vaccine, Varicella, varicella vaccine",
author = "Ngai, {Angela L.} and Staehle, {Brenda O.} and Kuter, {Barbara J.} and Cyanovich, {Nancy M.} and Iksung Cho and Holly Matthews and Paul Keller and Arvin, {Ann M.} and Barbara Watson and White, {C. J.} and Renner Anderson and Allan Arbeter and Steven Black and Block, {Stan L.} and Blumberg, {Dean A} and Brunell, {Philip A.} and Chartrand, {Steven A.} and Clements, {Dennis A.} and Penelope Dennehy and Harry Keyserling and Beth Nauert and Reisinger, {Keith S.} and Rennels, {Margaret B.} and Reuman, {Peter D.} and Shehab, {Ziad M.} and Starr, {Stuart E.} and Richard Tucker",
year = "1996",
doi = "10.1097/00006454-199601000-00011",
language = "English (US)",
volume = "15",
pages = "49--54",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children

AU - Ngai, Angela L.

AU - Staehle, Brenda O.

AU - Kuter, Barbara J.

AU - Cyanovich, Nancy M.

AU - Cho, Iksung

AU - Matthews, Holly

AU - Keller, Paul

AU - Arvin, Ann M.

AU - Watson, Barbara

AU - White, C. J.

AU - Anderson, Renner

AU - Arbeter, Allan

AU - Black, Steven

AU - Block, Stan L.

AU - Blumberg, Dean A

AU - Brunell, Philip A.

AU - Chartrand, Steven A.

AU - Clements, Dennis A.

AU - Dennehy, Penelope

AU - Keyserling, Harry

AU - Nauert, Beth

AU - Reisinger, Keith S.

AU - Rennels, Margaret B.

AU - Reuman, Peter D.

AU - Shehab, Ziad M.

AU - Starr, Stuart E.

AU - Tucker, Richard

PY - 1996

Y1 - 1996

N2 - Objective. To compare the safety and immunogenicity of a one- vs. two- dose regimen of Oka/Merck varicella vaccine in approximately 2000 healthy children 12 months to 12 years of age. Methodology. Subjects with a negative history of varicella were randomized to receive either one or two injections of the vaccine given 3 months apart and were followed for clinical reactions and serologic response (glycoprotein-based enzyme-linked immunosorbent assay). Results. Both one- and two-dose vaccine regimens were generally well- tolerated. The incidences of varicelliform rash and fever were less frequent after the second injection. However, as light increase in the incidence of injection site reactions was noted after the second injection; these were generally mild. Seroconversion rates by glycoprotein-based enzyme-linked immunosorbent assay were 98.2% (1700 of 1731) after one injection and 99.9% (717 of 718) after two injections. A significant (P < 0.001) boost in geometric mean titers was observed in children who received a second injection of vaccine 3 months after the first injection. Of the children who seroconverted at 6 weeks postregimen (one or two doses as assigned), 99.8% (528 of 529) of the one-dose group and 99.8% (473 of 474) of the two-dose group maintained antibody to varicella at 1 year with geometric mean titers of 19.5 and 31.2, respectively. Conclusions. Administration of a one- or two- dose regimen of the live Oka/Merck varicella vaccine (VARIVAX®) is immunogenic and is generally well-tolerated in healthy children 1 to 12 years old. Antibody to varicella persists in >99% of vaccinees 1 year after vaccination regardless of a one- or two-dose regimen. Long-term follow-up studies of this cohort of children may determine whether a two-dose regimen offers superior protection against chickenpox.

AB - Objective. To compare the safety and immunogenicity of a one- vs. two- dose regimen of Oka/Merck varicella vaccine in approximately 2000 healthy children 12 months to 12 years of age. Methodology. Subjects with a negative history of varicella were randomized to receive either one or two injections of the vaccine given 3 months apart and were followed for clinical reactions and serologic response (glycoprotein-based enzyme-linked immunosorbent assay). Results. Both one- and two-dose vaccine regimens were generally well- tolerated. The incidences of varicelliform rash and fever were less frequent after the second injection. However, as light increase in the incidence of injection site reactions was noted after the second injection; these were generally mild. Seroconversion rates by glycoprotein-based enzyme-linked immunosorbent assay were 98.2% (1700 of 1731) after one injection and 99.9% (717 of 718) after two injections. A significant (P < 0.001) boost in geometric mean titers was observed in children who received a second injection of vaccine 3 months after the first injection. Of the children who seroconverted at 6 weeks postregimen (one or two doses as assigned), 99.8% (528 of 529) of the one-dose group and 99.8% (473 of 474) of the two-dose group maintained antibody to varicella at 1 year with geometric mean titers of 19.5 and 31.2, respectively. Conclusions. Administration of a one- or two- dose regimen of the live Oka/Merck varicella vaccine (VARIVAX®) is immunogenic and is generally well-tolerated in healthy children 1 to 12 years old. Antibody to varicella persists in >99% of vaccinees 1 year after vaccination regardless of a one- or two-dose regimen. Long-term follow-up studies of this cohort of children may determine whether a two-dose regimen offers superior protection against chickenpox.

KW - children

KW - immunization

KW - vaccine

KW - Varicella

KW - varicella vaccine

UR - http://www.scopus.com/inward/record.url?scp=9044250842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044250842&partnerID=8YFLogxK

U2 - 10.1097/00006454-199601000-00011

DO - 10.1097/00006454-199601000-00011

M3 - Article

C2 - 8684876

AN - SCOPUS:9044250842

VL - 15

SP - 49

EP - 54

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 1

ER -